

Special Issue

Onco-Nephrology: From Molecular to Clinical Studies

Message from the Guest Editor

Onco-nephrology encompasses a wide range of clinical scenarios, including acute kidney injury, chronic kidney disease, electrolyte disorders, and glomerular diseases associated with malignancies or cancer therapies. It also addresses the increased cancer risk in patients with kidney disease, particularly transplant recipients.

As cancer treatments advance, including conventional chemotherapy, targeted therapies, immunotherapies, and cellular therapies, the need for specialized expertise in this area has grown exponentially. Specialists in this field play a crucial role in managing renal complications of cancer and its treatments, optimizing care strategies, and improving patient outcomes.

Moreover, it bridges the gap between nephrology and oncology, supporting clinical decision-making and addressing the unique challenges presented by the intersection of these fields.

This Special Issue explores the latest advancements in this crucial area, from molecular studies to clinical applications, highlighting its growing significance in modern medicine.

Guest Editor

Prof. Dr. Hans Kristian Lorenzo

Department of Nephrology, Bicêtre Hospital, Le Kremlin-Bicêtre, France/Paris-Saclay Medical School, Le Kremlin-Bicêtre, France

Deadline for manuscript submissions

12 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/213589

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)